MedTrace Logo

Effect of Local Anaesthetic Volume on Axillary Brachial Plexus Block Duration

NCT03163472 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-10-04

Study results available
· View outcomes & findings →

Summary

Axillary brachial plexus block is an safe, effective and widely used technique for providing surgical anesthesia at and below the elbow. Inadvertent intraneural and intravascular injections are the only significant risks. Traditionally, greater volumes of local anaesthetic have been administered to achieve successful axillary brachial plexus block, but recent studies have demonstrated that this can be achieved with even very low volumes of 2-4 mL lidocaine 1.5% per nerve or ultra low volume of 1 mL lidocaine 2% per nerve.

Administration of 30mL (vs 10 mL) lidocaine 2% with epinephrine 1:200 000 prolongs the sensory and motor block duration of ultrasound guided axillary brachial plexus block for elective upper limb surgical procedures.

Primary Outcome:

The primary outcome will be the overall duration of sensory block.

Secondary Outcomes:

Duration of motor block Time to onset of the block. The quality of block intraoperatively Time to first request of postoperative opioid analgesia. Total opioid consumption at 24 hours. The incidence of adverse effects perioperatively: nausea, dizziness, tinnitus, vomiting, convulsions or arrhythmia.

Conditions

  • Brachial Plexus Blockade

Interventions

PROCEDURE

Axillary brachial plexus block with 10 mL oof local anaesthetic

patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.

PROCEDURE

Axillary brachial plexus block with 30 ml of local anaesthetic

patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.

Sponsors & Collaborators

  • Cork University Hospital

    lead OTHER

Principal Investigators

  • Anil Ranganath, FCAI · Cork University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-14
Primary Completion
2013-08-07
Completion
2013-08-07

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03163472 on ClinicalTrials.gov